vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and PROVIDENT FINANCIAL SERVICES INC (PFS). Click either name above to swap in a different company.
PROVIDENT FINANCIAL SERVICES INC is the larger business by last-quarter revenue ($225.2M vs $177.4M, roughly 1.3× Pacira BioSciences, Inc.). PROVIDENT FINANCIAL SERVICES INC runs the higher net margin — 35.3% vs 1.6%, a 33.6% gap on every dollar of revenue. Over the past eight quarters, PROVIDENT FINANCIAL SERVICES INC's revenue compounded faster (17.3% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
The PNC Financial Services Group, Inc. is an American bank holding company and financial services corporation based in Pittsburgh, Pennsylvania. Its banking subsidiary, PNC Bank, operates in 27 states and the District of Columbia, with 2,629 branches and 9,523 ATMs. PNC Bank is one of the largest banks in the US by assets and by number of branches, deposits, and ATMs.
PCRX vs PFS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $225.2M |
| Net Profit | $2.9M | $79.4M |
| Gross Margin | — | — |
| Operating Margin | 3.9% | — |
| Net Margin | 1.6% | 35.3% |
| Revenue YoY | 5.0% | — |
| Net Profit YoY | — | 24.0% |
| EPS (diluted) | $0.07 | $0.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | $225.2M | ||
| Q4 25 | $196.9M | $225.7M | ||
| Q3 25 | $179.5M | $221.8M | ||
| Q2 25 | $181.1M | $214.2M | ||
| Q1 25 | $168.9M | $208.8M | ||
| Q4 24 | $187.3M | $205.9M | ||
| Q3 24 | $168.6M | $210.6M | ||
| Q2 24 | $178.0M | $163.8M |
| Q1 26 | $2.9M | $79.4M | ||
| Q4 25 | — | — | ||
| Q3 25 | $5.4M | $71.7M | ||
| Q2 25 | $-4.8M | $72.0M | ||
| Q1 25 | $4.8M | $64.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-143.5M | $46.4M | ||
| Q2 24 | $18.9M | $-11.5M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 49.7% | ||
| Q3 25 | 3.5% | 45.8% | ||
| Q2 25 | 4.7% | 47.8% | ||
| Q1 25 | 1.2% | 44.0% | ||
| Q4 24 | 13.2% | 30.5% | ||
| Q3 24 | -82.8% | 31.0% | ||
| Q2 24 | 15.9% | -13.0% |
| Q1 26 | 1.6% | 35.3% | ||
| Q4 25 | — | — | ||
| Q3 25 | 3.0% | 32.3% | ||
| Q2 25 | -2.7% | 33.6% | ||
| Q1 25 | 2.8% | 30.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -85.1% | 22.0% | ||
| Q2 24 | 10.6% | -7.0% |
| Q1 26 | $0.07 | $0.61 | ||
| Q4 25 | $0.05 | $0.64 | ||
| Q3 25 | $0.12 | $0.55 | ||
| Q2 25 | $-0.11 | $0.55 | ||
| Q1 25 | $0.10 | $0.49 | ||
| Q4 24 | $0.38 | $0.37 | ||
| Q3 24 | $-3.11 | $0.36 | ||
| Q2 24 | $0.39 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $222.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $653.9M | $2.9B |
| Total Assets | $1.2B | $25.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | $222.1M | ||
| Q4 25 | $238.4M | $209.1M | ||
| Q3 25 | $246.3M | $299.2M | ||
| Q2 25 | $445.9M | $258.0M | ||
| Q1 25 | $493.6M | $234.1M | ||
| Q4 24 | $484.6M | $205.9M | ||
| Q3 24 | $453.8M | $244.0M | ||
| Q2 24 | $404.2M | $290.5M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | $2.9B | ||
| Q4 25 | $693.1M | $2.8B | ||
| Q3 25 | $727.2M | $2.8B | ||
| Q2 25 | $757.8M | $2.7B | ||
| Q1 25 | $798.5M | $2.7B | ||
| Q4 24 | $778.3M | $2.6B | ||
| Q3 24 | $749.6M | $2.6B | ||
| Q2 24 | $879.3M | $2.6B |
| Q1 26 | $1.2B | $25.2B | ||
| Q4 25 | $1.3B | $25.0B | ||
| Q3 25 | $1.3B | $24.8B | ||
| Q2 25 | $1.5B | $24.5B | ||
| Q1 25 | $1.6B | $24.2B | ||
| Q4 24 | $1.6B | $24.1B | ||
| Q3 24 | $1.5B | $24.0B | ||
| Q2 24 | $1.6B | $24.1B |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
PFS
| Net Interest Income | $193.7M | 86% |
| Noninterest Income | $31.5M | 14% |
